Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Lion Biotechnologies enters two agreements regarding TIL products

Sep. 19, 2016

Dosing begins in Zymeworks' phase I study of ZW-25

Sep. 19, 2016

OncoImmune, Pfizer enter agreement for anti-CTLA-4 monoclonal antibody

Sep. 19, 2016

EMA's CHMP recommends conditional approval of Lilly's olaratumab

Sep. 16, 2016

National Cancer Center of Japan and Ono sign comprehensive research collaboration agreement

Sep. 16, 2016

DSMB recommends continuation of Celsion's phase Ib OVATION study

Sep. 16, 2016

SELLAS Life Sciences enters CRADA to develop AML-MRD assay

Sep. 15, 2016

Phase I data for CAR-modified T-cell immunotherapy in patients with non-Hodgkin's lymphoma

Sep. 15, 2016

Morphotek and Fox Chase Cancer Center enter research agreement

Sep. 14, 2016

First patient dosed in Xencor's phase I study of Xmab-14045

Sep. 13, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.